Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aminoglycoside therapy. Current use and future prospects.

R Janknegt1

  • 1Department of Clinical Pharmacy, Maasland Hospital, Sittard, The Netherlands.

Pharmaceutisch Weekblad. Scientific Edition
|June 22, 1990
PubMed
Summary

Aminoglycosides remain crucial for severe infections, often combined with beta-lactams. While once-daily dosing shows promise, more research is needed to confirm efficacy and safety before widespread recommendation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The nocebo effect challenges the non-medical infliximab switch in practice.

European journal of clinical pharmacology·2018
Same author

The use of an electronic clinical rule to discontinue chronically used benzodiazepines and related Z drugs.

European journal of clinical pharmacology·2017
Same author

Usually Available Clinical and Laboratory Data Are Insufficient for a Valid Medication Review: A Crossover Study.

The journal of nutrition, health & aging·2016
Same author

SWAB/NVALT (Dutch Working Party on Antibiotic Policy and Dutch Association of Chest Physicians) guidelines on the management of community-acquired pneumonia in adults.

The Netherlands journal of medicine·2012
Same author

[Optimisation of the antibiotic policy in the Netherlands. X. The SWAB guideline for antimicrobial treatment of complicated urinary tract infections].

Nederlands tijdschrift voor geneeskunde·2006
Same author

[Optimizing the antibiotics policy in The Netherlands. VIII. Revised SWAB guidelines for antimicrobial therapy in adults with community-acquired pneumonia].

Nederlands tijdschrift voor geneeskunde·2005

Area of Science:

  • Microbiology
  • Pharmacology
  • Toxicology
  • Clinical Medicine

Background:

  • Aminoglycosides are vital for treating serious infections, including those in neutropenic patients, endocarditis, and Pseudomonas aeruginosa infections.
  • They are frequently used in combination with beta-lactams for enhanced efficacy.
  • Monotherapy with streptomycin is reserved for rarer conditions like tularemia and bubonic plague.

Purpose of the Study:

  • To review the microbiological, pharmacokinetic, toxicological, and clinical aspects of aminoglycosides.
  • To evaluate the potential of once-daily dosing regimens for aminoglycosides.
  • To provide guidance on selecting appropriate aminoglycosides based on current evidence.

Main Methods:

  • Review of existing literature on aminoglycosides.
  • Analysis of experimental studies supporting once-daily dosing.
  • Consideration of clinical data regarding efficacy, resistance, and toxicity.

Main Results:

  • Aminoglycosides are essential in combination therapy for specific severe infections.
  • Experimental data suggests once-daily aminoglycoside dosing may offer comparable efficacy with reduced toxicity.
  • Limited prospective studies exist, necessitating further research on once-daily regimens' efficacy, resistance, and safety.

Conclusions:

  • Aminoglycosides continue to play a significant role in treating critical infections.
  • Once-daily dosing requires more robust clinical validation before recommendation.
  • Selection should prioritize local sensitivity patterns and cost, with amikacin potentially becoming the preferred agent if costs decrease.

Related Experiment Videos